NMDA receptor activity regulates transcription of antioxidant pathways

Article metrics

How neurons might protect themselves from free radical damage has been a mystery. A new study suggests that synaptic NMDA receptor activity affords neuroprotection by regulating oxidation-reduction (redox) pathways via transcription.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Synaptic NMDAR control of Trx and Prx activity for neuroprotection.

References

  1. 1

    Papadia, S. et al. Nat. Neurosci. 11, 476–487 (2008).

  2. 2

    Fang, J., Nakamura, T., Cho, D.H., Gu, Z. & Lipton, S.A. Proc. Natl. Acad. Sci. USA 104, 18742–18747 (2007).

  3. 3

    Gu, Z. et al. Science 297, 1186–1190 (2002).

  4. 4

    Rhee, S.G., Jeong, W., Chang, T.S. & Woo, H.A. Kidney Int. Suppl. 106, S3–S8 (2007).

  5. 5

    Hardingham, G.E. & Bading, H. Trends Neurosci. 26, 81–89 (2003).

  6. 6

    Lipton, S.A. Nat. Rev. Neurosci. 8, 803–808 (2007).

  7. 7

    Lipton, S.A. Nat. Rev. Drug Discov. 5, 160–170 (2006).

  8. 8

    Liu, Y. et al. J. Neurosci. 27, 2846–2857 (2007).

  9. 9

    Chung, K.K. et al. Science 304, 1328–1331 (2004).

  10. 10

    Yao, D. et al. Proc. Natl. Acad. Sci. USA 101, 10810–10814 (2004).

  11. 11

    Lipton, S.A. et al. Science 308, 1870 (2005).

  12. 12

    Uehara, T. et al. Nature 441, 513–517 (2006).

Download references

Author information

Ethics declarations

Competing interests

Dr. Lipton is the named inventor on patents for the use of the clinically-approved and marketed drug, memantine (Namenda®), in the treatment of neurodegenerative diseases. He has no direct ownership in memantine, but under the rules of the institution where this work was performed, Harvard University, he participates in a royalty-sharing plan administered by Harvard Medical School and Children's Hospital, Bostan.

Rights and permissions

Reprints and Permissions

About this article

Further reading